Alzheimer's disease: Clinical trials and the amyloid hypothesis

Annals of the Academy of Medicine Singapore

Volumn 40, Issue 7, 2011, Pages 304-306

  Cummings, Jeffrey ^a  

^a CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BAPINEUZUMAB; BETA SECRETASE INHIBITOR; GAMMA SECRETASE INHIBITOR; HOMOTAURINE; PRESENILIN 1; PRESENILIN 2; ROSIGLITAZONE; TARENFLURBIL;

ALZHEIMER DISEASE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; EDITORIAL; GENE MUTATION; HUMAN; HYPOTHESIS; NONHUMAN; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN FUNCTION;

EID: 80051487235     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Editorial

References (27)

1. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011;7:137-52.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-6.
3. Wan HI, Jacobsen JS, Rutkowski JL, Feuerstein GZ. Translational medicine lessons from flurizan's failure in Alzheimer's disease (AD) trial: Implication for future drug discovery and development for AD. Clin Transl Sci 2009;2:242-7.
4. Cummings J. What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease? Biol Psychiatry 2010;68:876-8.
5. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al; Bapineuzumab 201 Clinical Trial Investigators. A Phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061-70.
6. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010;330:1774.
7. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative. Ann Neurol 2009;65:403-13.
8. Sojkova J, Zhou Y, An Y, Kraut MA, Ferrucci L, Wong DF, et al. Longitudinal patterns of β-amyloid deposition in nondemented older adults. Arch Neurol 2011;68:644-9.
9. Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 2011;69:181-92.
10. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008;65:1509-17.
11. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomized, placebo-controlled phase I trial. Lancet 2008;372:216-23.
12. Buckner RL, Sepulcre J, Talukdar T, Krienen FM, Liu H, Hedden T, et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci 2009;29:1860-73.
13. Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron 2010;68:270-81.
14. Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 2011;63:1.
15. Mitchell SL, Teno JM, Kiely DK, Shaffer ML, Jones RN, Prigerson HG, et al. The clinical course of advanced dementia. N Engl J Med 2009;361:1529-38.
16. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010;9:1118-27.
17. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-46.
18. Ashe KH, Zahs KR. Probing the biology of Alzheimer's disease in mice. Neuron 2010;66:631-45.
19. Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. Soluble amyloid beta-protein dimmers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A. 2011;108:5819-24.
20. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 2008;451:720-4.
21. Gold G, Kovari E, Corte G, Herrmann FR, Canuto A, Bussiere T, et al. Clinical validity of A beta-protein deposition staging in brain aging and Alzheimer disease. J Neuropathol Exp Neurol 2001;60:946-52.
22. Di Patre PL, Read SL, Cummings JL, Tomiyasu U, Vartavarian LM, Secor DL, et al. Progression of clinical deterioration and pathological changes in patients with Alzheimer disease evaluated at biopsy and autopsy. Arch Neurol 1999;56:1254-61.
23. Cummings JL. Biomarkers in Alzheimer's disease drug development. Alzheimers Dement 2011;7:e13-44.
24. Pritchard SM, Dolan PJ, Vitkus A, Johnson GV. The toxicity of tau in Alzheimer Disease: turnover, targets and potential therapeutics. J Cell Mol Med 2011 Feb 23. doi: 10.1111/j.1582-4934.2011.01273.x.
25. Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, Kayed R. Tau oligomers as potencial target for immunotherapy for Alzheimer disease and tauopathies. Curr Alzheimer Res 2011; in press.
26. Giannakopoulos P, Herrmann FR, Bussière T, Bouras C, Kövari E, Perl DP, et al. Tangle and neuron numbers, but not amyloid load, predict congnitive status in Alzheimer's disease. Neurology 2003;60:1495-500.
27. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010;9:702-16.